SAL0140 clinical trials
Also written SAL0140.
How each study uses SAL0140 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the SAL0140 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test SAL0140.
- Mar 2027A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Uncontrolled HypertensionPhase 2 · Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Apr 2027A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Primary AldosteronismPhase 2 · Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Oct 2027A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Chronic Kidney DiseasePhase 2 · Shenzhen Salubris Pharmaceuticals Co., Ltd.
Studies
Open first, then newest update. How each study uses SAL0140 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Uncontrolled HypertensionRecruitingPhase 2Shenzhen Salubris Pharmaceuticals Co., Ltd.NCT07654140Written as SAL0140
- A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Chronic Kidney DiseaseNot yet recruitingPhase 2Shenzhen Salubris Pharmaceuticals Co., Ltd.NCT07647133Written as SAL0140 Tablets
- A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Primary AldosteronismNot yet recruitingPhase 2Shenzhen Salubris Pharmaceuticals Co., Ltd.NCT07646535Written as SAL0140 Tablets
- SAL0140 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese PopulationRecruitingPhase 1Shenzhen Salubris Pharmaceuticals Co., Ltd.NCT07051603Written as SAL0140